Vivos Therapeutics (NASDAQ:VVOS) & Tandem Diabetes Care (NASDAQ:TNDM) Head-To-Head Survey

Tandem Diabetes Care (NASDAQ:TNDM) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 1.4% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Tandem Diabetes Care and Vivos Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01 billion	1.38	-$204.71 million	($0.72)	-27.88
Vivos Therapeutics	$17.44 million	0.11	-$21.17 million	($1.90)	-0.05

Vivos Therapeutics has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tandem Diabetes Care and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-4.58%	-35.61%	-4.53%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Analyst Ratings

This is a summary of current ratings and price targets for Tandem Diabetes Care and Vivos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1	12	9	1	2.43
Vivos Therapeutics	1	1	2	0	2.25

Tandem Diabetes Care currently has a consensus target price of $27.18, suggesting a potential upside of 35.45%. Vivos Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 2,757.14%. Given Vivos Therapeutics’ higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Tandem Diabetes Care.

Risk & Volatility

Tandem Diabetes Care has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.37, meaning that its stock price is 537% more volatile than the S&P 500.

Summary

Tandem Diabetes Care beats Vivos Therapeutics on 10 of the 15 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

About Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.